Friday, October 10, 2014

Texas AG opens lawsuit against AstraZeneca for the illegal marketing of Seroquel

Texas AG opens lawsuit against AstraZeneca for criminal fraud and the illegal marketing of Seroquel

Not that this news will have much of an effect on this politically connected corporate giant, or will it bring any solace to the countless thousands of lives lost, ruined, and cask aside by this criminal corporation.

Those that have followed the Pharmaceutical corporate crime wave over the past couple of decades are asking the following question once again: What "CIA" Corporate Integrity Agreement?

This litigation has all the makings of just another chump change settlement where AstraZeneca pays a small fine and admits no wrong doing. It's just the way in works today in the United States of America. AZ is to big and connected to be held accountable...AstraZeneca is after all a member of the elite ruling class CLUB, and you the average Joe/Jane citizen are not invited to their club house party.

The Wall Street Journal, veteran and well respected reporter Ed Silverman of Pharmalot fame are reporting:

Texas AG Lawsuit Claims AstraZeneca Improperly Marketed Seroquel

The Texas Attorney General has filed a lawsuit this week against AstraZeneca that alleges the drug maker illegally marketed its Seroquel antipsychotic pill for unapproved uses, paid kickbacks to physician and state health officials, and subsequently caused the state Medicaid program to overpay for the medicine.

The lawsuit, which was filed in a state court in Texas, builds on claims in lawsuits that were filed by two former AstraZeneca sales reps, who alleged the drug maker used various tactics to induce physicians to prescribe different versions of the Seroquel pill.
As an example, the drug maker allegedly paid $465,000 to a pair of unidentified state mental health officials “with the power to influence formulary decisions within the state hospital system,” according to the lawsuit. A formulary is listed of drugs for which an insurer offers reimbursement.

To read the complete article:

Related Links: